$CVS
CVS HEALTH Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000006480324000016 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$91.23B	$88.44B
YoY Change	2.6%	3.7%
Cost Of Revenue	$50.00B	$75.88B
YoY Change	-6.61%	47.46%
Gross Profit	$41.24B	$12.56B
YoY Change	16.54%	-62.86%
Gross Profit Margin	45.2%	14.2%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$1.138B
YoY Change		13.69%
% of Gross Profit		9.06%
Operating Expenses	$10.34B	$10.29B
YoY Change	-67.34%	-65.73%
Operating Profit	$3.045B	$2.271B
YoY Change	-18.36%	-34.1%
Interest Expense	-$732.0M	-$716.0M
YoY Change	6.71%	-221.56%
% of Operating Profit	-24.04%	-31.53%
Other Income/Expense, Net	$24.00M	$25.00M
YoY Change	9.09%	13.64%
Pretax Income	$2.337B	$1.580B
YoY Change	-9.07%	-45.12%
Income Tax	$569.0M	$456.0M
% Of Pretax Income	24.35%	28.86%
Net Earnings	$1.770B	$1.113B
YoY Change	-6.89%	-47.89%
Net Earnings / Revenue	1.94%	1.26%
Basic Earnings Per Share	$1.41	$0.88
Diluted Earnings Per Share	$1.41	$0.88
COMMON SHARES
Basic Shares Outstanding	1.255B shares	1.258B shares
Diluted Shares Outstanding	1.259B shares	1.267B shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.26B	$13.09B
YoY Change	-3.7%	-26.13%
Cash & Equivalents	$12.51B	$9.801B
Short-Term Investments	$3.755B	$3.288B
Other Short-Term Assets	$5.237B	$5.821B
YoY Change	29.89%	54.53%
Inventory	$16.07B	$16.35B
Prepaid Expenses
Receivables	$32.39B	$10.59B
Other Receivables	$4.634B	$21.63B
Total Short-Term Assets	$69.95B	$67.47B
YoY Change	3.24%	-1.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.93B	$30.08B
YoY Change	-2.51%	133.7%
Goodwill	$91.27B	$91.27B
YoY Change	0.01%	8.58%
Intangibles	$28.31B	$28.77B
YoY Change	-6.0%	9.11%
Long-Term Investments	$25.03B	$24.07B
YoY Change	13.18%	11.39%
Other Assets	$4.798B	$8.072B
YoY Change	-40.9%	67.33%
Total Long-Term Assets	$182.5B	$182.3B
YoY Change	0.12%	6.83%
TOTAL ASSETS
Total Short-Term Assets	$69.95B	$67.47B
Total Long-Term Assets	$182.5B	$182.3B
Total Assets	$252.5B	$249.7B
YoY Change	0.96%	4.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$52.49B	$50.37B
YoY Change	14.65%	15.88%
Accrued Expenses	$21.16B	$24.14B
YoY Change	-13.18%	12.2%
Deferred Revenue	$128.0M	$117.0M
YoY Change	-20.5%	-13.97%
Short-Term Debt	$0.00	$2.719B
YoY Change	-100.0%
Long-Term Debt Due	$3.731B	$3.731B
YoY Change	166.12%	109.84%
Total Short-Term Liabilities	$81.39B	$83.32B
YoY Change	2.75%	11.01%
LONG-TERM LIABILITIES
Long-Term Debt	$62.64B	$57.69B
YoY Change	1.99%	2.2%
Other Long-Term Liabilities	$5.526B	$30.40B
YoY Change	-82.65%	355.64%
Total Long-Term Liabilities	$5.526B	$88.09B
YoY Change	-94.08%	1220.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.39B	$83.32B
Total Long-Term Liabilities	$5.526B	$88.09B
Total Liabilities	$177.4B	$175.8B
YoY Change	0.01%	4.78%
SHAREHOLDERS EQUITY
Retained Earnings	$62.80B	$61.87B
YoY Change	6.67%	7.13%
Common Stock	$18.00M	$18.00M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.93B	$73.97B
YoY Change
Total Liabilities & Shareholders Equity	$252.5B	$249.7B
YoY Change	0.96%	4.35%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$1.770B	$1.113B
YoY Change	-6.89%	-47.89%
Depreciation, Depletion And Amortization		$1.138B
YoY Change		13.69%
Cash From Operating Activities	$3.089B	$4.903B
YoY Change	-47.71%	-34.08%
INVESTING ACTIVITIES
Capital Expenditures	$638.0M	$705.0M
YoY Change	7.95%	-28.35%
Acquisitions		$25.00M
YoY Change		-99.65%
Other Investing Activities	-$987.0M	-$1.389B
YoY Change	-89.9%	4380.65%
Cash From Investing Activities	-$1.625B	-$2.094B
YoY Change	-84.32%	-75.41%
FINANCING ACTIVITIES
Cash Dividend Paid		$840.0M
YoY Change		7.83%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$18.00M
YoY Change		-95.03%
Cash From Financing Activities	1.249B	-1.227B
YoY Change	-65.55%	-145.01%
NET CHANGE
Cash From Operating Activities	3.089B	4.903B
Cash From Investing Activities	-1.625B	-2.094B
Cash From Financing Activities	1.249B	-1.227B
Net Change In Cash	2.713B	1.582B
YoY Change	-427.66%	-4.12%
FREE CASH FLOW
Cash From Operating Activities	$3.089B	$4.903B
Capital Expenditures	$638.0M	$705.0M
Free Cash Flow	$2.451B	$4.198B
YoY Change	-53.9%	-34.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	30391000000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	24352000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	454000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	334000000	usd
CY2024Q1	us-gaap	Revenues Revenues	88437000000	usd
CY2023Q1	us-gaap	Revenues Revenues	85278000000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48073000000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51455000000	usd
CY2024Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	27803000000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	20448000000	usd
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2024Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	10290000000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	9580000000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	86166000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	81832000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2271000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3446000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	716000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	589000000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1580000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2879000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	456000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	737000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1124000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1113000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	2136000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.66
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.88
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.65
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1260000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1283000000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1267000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1291000000	shares
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.665
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.605
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1124000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-108000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	470000000	usd
CY2024Q1	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	68000000	usd
CY2023Q1	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-74000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-4000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-6000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-44000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1080000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2531000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1069000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2525000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9801000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8196000000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	3288000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	3259000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32217000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35227000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	16346000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18025000000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5821000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3151000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	67473000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	67858000000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	24074000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	23019000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13037000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13183000000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17045000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17252000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	91272000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	91272000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28770000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29234000000	usd
CY2024Q1	us-gaap	Separate Account Assets SeparateAccountAssets	3271000000	usd
CY2023Q4	us-gaap	Separate Account Assets SeparateAccountAssets	3250000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4801000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4660000000	usd
CY2024Q1	us-gaap	Assets Assets	249743000000	usd
CY2023Q4	us-gaap	Assets Assets	249728000000	usd
CY2024Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	13717000000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	14897000000	usd
CY2024Q1	cvs	Pharmacy Claims And Discounts Payable Current PharmacyClaimsAndDiscountsPayableCurrent	22289000000	usd
CY2023Q4	cvs	Pharmacy Claims And Discounts Payable Current PharmacyClaimsAndDiscountsPayableCurrent	22874000000	usd
CY2024Q1	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	14368000000	usd
CY2023Q4	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	12049000000	usd
CY2024Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	1081000000	usd
CY2023Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	1326000000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22350000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22189000000	usd
CY2024Q1	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1158000000	usd
CY2023Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1141000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1906000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1741000000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	2719000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	200000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3731000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2772000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	83319000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79189000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15742000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16034000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	57694000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	58638000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4184000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4311000000	usd
CY2024Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3271000000	usd
CY2023Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3250000000	usd
CY2024Q1	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5178000000	usd
CY2023Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5459000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6205000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6211000000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	175593000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	173092000000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1771000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1252000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1768000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1288000000	shares
CY2024Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	49209000000	usd
CY2023Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48992000000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	519000000	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	480000000	shares
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	36773000000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	33838000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	61873000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	61604000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-341000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-297000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	73968000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	76461000000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	182000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	175000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74150000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76636000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	249743000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	249728000000	usd
CY2024Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	84997000000	usd
CY2023Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	87798000000	usd
CY2024Q1	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	44824000000	usd
CY2023Q1	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	50223000000	usd
CY2024Q1	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	24894000000	usd
CY2023Q1	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	19757000000	usd
CY2024Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	9677000000	usd
CY2023Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	9958000000	usd
CY2024Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	407000000	usd
CY2023Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	426000000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1043000000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	773000000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	63000000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	75000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4903000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7438000000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2153000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1891000000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3545000000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2358000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	705000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	984000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	25000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7094000000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-28000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-31000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2094000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8514000000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	2519000000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5951000000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	18000000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	362000000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3027000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2018000000	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	840000000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	779000000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	203000000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	31000000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	34000000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-33000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-128000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1227000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2726000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1582000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1650000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8525000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10107000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14955000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1124000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1138000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	137000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	103000000	usd
CY2024Q1	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	-217000000	usd
CY2023Q1	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	155000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3008000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	751000000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1660000000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-828000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2836000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1255000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1410000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1203000000	usd
CY2024Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	2253000000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	4382000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	46000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2036000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4903000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7438000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76636000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	1124000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-44000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000000	usd
CY2024Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	2962000000	usd
CY2024Q1	us-gaap	Dividends Common Stock DividendsCommonStock	844000000	usd
CY2024Q1	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-4000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74150000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	122000000	usd
CY2023Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	1962000000	usd
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	781000000	usd
CY2023Q1	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-99000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71580000000	usd
CY2024Q1	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q4	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q1	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2022Q4	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2024Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2023Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2024Q1	cvs	Number Of Pharmacy Plan Members NumberOfPharmacyPlanMembers	90000000	people
CY2024Q1	cvs	Number Of Patients Served Per Year NumberOfPatientsServedPerYear	800000	patient
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2023	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9801000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8196000000	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	51000000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	90000000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	255000000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	239000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10107000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8525000000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	10586000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	11908000000	usd
CY2024Q1	cvs	Vendor And Manufacturer Receivables VendorAndManufacturerReceivables	12681000000	usd
CY2023Q4	cvs	Vendor And Manufacturer Receivables VendorAndManufacturerReceivables	15711000000	usd
CY2024Q1	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5420000000	usd
CY2023Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	3714000000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3530000000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3894000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32217000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35227000000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	402000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	343000000	usd
CY2023Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1502000000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1219000000	usd
CY2024Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	134000000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	135000000	usd
CY2024Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	76000000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	64000000	usd
CY2024Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1560000000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1290000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	454000000	usd
CY2024Q1	us-gaap	Revenues Revenues	88437000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	334000000	usd
CY2023Q1	us-gaap	Revenues Revenues	85278000000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	10586000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	11908000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	117000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	149000000	usd
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	5000000000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	3288000000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	24074000000	usd
CY2024Q1	us-gaap	Investments Investments	27362000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	3259000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	23019000000	usd
CY2023Q4	us-gaap	Investments Investments	26278000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	23308000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	191000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	873000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22626000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22282000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	267000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	836000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21713000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	1262000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1245000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	8032000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	7836000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	4588000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4463000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	3915000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	3703000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	23308000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22626000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	2635	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4578000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	47000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	6576	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	9664000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	826000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	9211	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	14242000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	873000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	1182	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1932000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	28000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	7018	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10616000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	808000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	8200	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12548000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	836000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	1107000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	19000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	5528000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	235000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	2504000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	181000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	2470000000	usd
CY2024Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	268000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	14242000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	873000000	usd
CY2024Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	484000000	usd
CY2023Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	449000000	usd
CY2024Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	12000000	usd
CY2023Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	10000000	usd
CY2024Q1	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	472000000	usd
CY2023Q1	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	439000000	usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-18000000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-105000000	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	454000000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	334000000	usd
CY2024Q1	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	10000000	usd
CY2024Q1	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	usd
CY2023Q1	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	24000000	usd
CY2023Q1	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-1000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1265000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1341000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	8000000	usd
CY2023Q1	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	21000000	usd
CY2024Q1	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-4000000	usd
CY2023Q1	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-9000000	usd
CY2024Q1	us-gaap	Policyholder Funds PolicyholderFunds	329000000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	349000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	3000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	52000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	111000000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	29000000	usd
CY2024Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the three months ended March 31, 2024 and 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,067 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,733 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,413 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive loss on the unaudited condensed consolidated balance sheets. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span>Total incurred health care costs for the three months ended March 31, 2024 and 2023 in the table above exclude $23 million and $22 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $47 million and $51 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets.
CY2023Q4	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	12049000000	usd
CY2023Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	5000000	usd
CY2023Q4	us-gaap	Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax	23000000	usd
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	12067000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	28212000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-479000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	27733000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	16263000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	9150000000	usd
CY2024Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	25413000000	usd
CY2024Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	14387000000	usd
CY2024Q1	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	4000000	usd
CY2024Q1	us-gaap	Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax	23000000	usd
CY2024Q1	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	14368000000	usd
CY2024Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-479000000	usd
CY2024Q1	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	11000000000	usd
CY2023Q4	us-gaap	Policyholder Funds PolicyholderFunds	332000000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	345000000	usd
CY2024Q1	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	9000000	usd
CY2023Q1	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	-4000000	usd
CY2024Q1	us-gaap	Policyholder Account Balance Policy Charge PolicyholderAccountBalancePolicyCharge	1000000	usd
CY2023Q1	us-gaap	Policyholder Account Balance Policy Charge PolicyholderAccountBalancePolicyCharge	0	usd
CY2024Q1	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	4000000	usd
CY2023Q1	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	7000000	usd
CY2024Q1	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	3000000	usd
CY2023Q1	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	3000000	usd
CY2024Q1	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	-6000000	usd
CY2024Q1	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0430
CY2023Q1	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0455
CY2024Q1	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2023Q1	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2024Q1	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	320000000	usd
CY2023Q1	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	332000000	usd
CY2023Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3250000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2024Q1	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	201000000	usd
CY2023Q1	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	246000000	usd
CY2024Q1	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	93000000	usd
CY2023Q1	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	0	usd
CY2024Q1	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	223000000	usd
CY2023Q1	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	260000000	usd
CY2024Q1	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	128000000	usd
CY2023Q1	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	23000000	usd
CY2024Q1	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	-2000000	usd
CY2023Q1	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	0	usd
CY2024Q1	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	6000000	usd
CY2023Q1	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	-6000000	usd
CY2024Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3271000000	usd
CY2023Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3231000000	usd
CY2024Q1	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2201000000	usd
CY2023Q1	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2142000000	usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.665
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.605
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-44000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1113000000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1113000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2136000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2136000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1260000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1283000000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1267000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1291000000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.66
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.88
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.65
CY2024Q1	cvs	Guarantor Obligations Number Of Leases GuarantorObligationsNumberOfLeases	63	lease
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2024Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	87983000000	usd
CY2024Q1	us-gaap	Net Investment Income NetInvestmentIncome	454000000	usd
CY2024Q1	us-gaap	Revenues Revenues	88437000000	usd
CY2024Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	2957000000	usd
CY2023Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	84944000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	334000000	usd
CY2023Q1	us-gaap	Revenues Revenues	85278000000	usd
CY2023Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4370000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2271000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3446000000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	508000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	402000000	usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-18000000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-105000000	usd
CY2024Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	60000000	usd
CY2023Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	43000000	usd
CY2024Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-100000000	usd
CY2023Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2024Q1	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	0	usd
CY2023Q1	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	25000000	usd
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2024Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	2957000000	usd
CY2023Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4370000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000064803-24-000016-index-headers.html	Edgar Link	pending
0000064803-24-000016-index.html	Edgar Link	pending
0000064803-24-000016.txt	Edgar Link	pending
0000064803-24-000016-xbrl.zip	Edgar Link	pending
a03312024ex101.htm	Edgar Link	pending
a03312024ex102.htm	Edgar Link	pending
a03312024ex103.htm	Edgar Link	pending
a03312024ex151.htm	Edgar Link	pending
a03312024ex311.htm	Edgar Link	pending
a03312024ex312.htm	Edgar Link	pending
a03312024ex321.htm	Edgar Link	pending
a03312024ex322.htm	Edgar Link	pending
cvs-20240331.htm	Edgar Link	pending
cvs-20240331.xsd	Edgar Link	pending
cvs-20240331_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
cvs-20240331_def.xml	Edgar Link	unprocessable
cvs-20240331_lab.xml	Edgar Link	unprocessable
cvs-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvs-20240331_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cvs-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS HEALTH Corp Stock $cvs

2024 Q2 Form 10-Q Financial Statement

#000006480324000016 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS HEALTH Corp Stock $cvs

2024 Q2 Form 10-Q Financial Statement

#000006480324000016 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS HEALTH Corp Stock $cvs